The FDA-approved constipation drug Ruby Protonone is the first of its time

Source: CDE Website Ruby Prostone is a limited chloroion channel activator that selectively activates type 2 chloride ion channels (ClC-2) located on the cell membrane of the epithelial tip of the gastrointestinal epithelial cavity, increasing the secretion of bowel fluid and the movement of the intestine, thereby increasing detocation, reducing symptoms of chronic idyl constipation, and without altering the concentration of sodium and potassium in the plasma.
U.S. market in 2006, ruby progesterone is the FDA's first approved chemical constipation treatment and the only prescription drug approved for long-term chronic idiotic constipation in Switzerland.
compared with other laxatives, ruby progesterone not only has good constipation treatment effect, but also has a low rate of long-term application of drug resistance, but also has the advantage of small doses.
Figure 1: Global sales of Ruby's progesterone (in millions of yen) Source: Minernet Multinational Listed Company Sales Co., Ltd. Takeda Pharmaceuticals of Japan paid no more than $49 million in 2014 for the global development and use of Ruby's protonone (except in Japan and China), which has declined slightly in recent years, achieving sales of 28.1 billion yen in 2019.
Figure 2: Ruby prostatone capsule declaration source: Mi Net one-click retrieval MiNet data show that although there is currently no Ruby prostatone-related preparations approved for listing, but there are many enterprises began to lay out.
, Nanjing Zhengtianqing first to imitate 3 categories of production, is expected to win the first imitation.
In addition, HOWSON, Zhengda Tianqing Pharmaceuticals, Suzhou Longco Biologicals and other enterprises submitted clinical applications for the product, of which Howson, Zhengda Tianqing Pharmaceuticals, Beijing Xili European Biological products have been approved clinically.
source: Minet database